About sinovac biotech - SVA
Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.
SVA At a Glance
Sinovac Biotech Ltd.
No. 39 Shangdi Xi Road
Beijing, Beijing 100085
| Phone | 86-10-5693-1800 | Revenue | 448.27M | |
| Industry | Pharmaceuticals: Major | Net Income | -99,918,000.00 | |
| Sector | Health Technology | Employees | 3,037 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
SVA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
SVA Efficiency
| Revenue/Employee | 147,602.568 |
| Income Per Employee | -32,900.23 |
| Receivables Turnover | 0.995 |
| Total Asset Turnover | 0.032 |
SVA Liquidity
| Current Ratio | 10.306 |
| Quick Ratio | 10.184 |
| Cash Ratio | 9.782 |
SVA Profitability
| Gross Margin | 59.507 |
| Operating Margin | -121.963 |
| Pretax Margin | -34.139 |
| Net Margin | -22.29 |
| Return on Assets | -0.72 |
| Return on Equity | -1.133 |
| Return on Total Capital | -1.109 |
| Return on Invested Capital | -1.116 |
SVA Capital Structure
| Total Debt to Total Equity | 3.433 |
| Total Debt to Total Capital | 3.319 |
| Total Debt to Total Assets | 2.189 |
| Long-Term Debt to Equity | 2.493 |
| Long-Term Debt to Total Capital | 2.41 |